Definitive-intent radiotherapy for sinonasal carcinoma in cats: a multicenter retrospective assessment by Stiborova, Katerina et al.








Definitive-intent radiotherapy for sinonasal carcinoma in cats: a multicenter
retrospective assessment
Stiborova, Katerina ; Meier, Valeria S ; Takada, Marilia ; Turek, Michelle ; Poirier, Valerie J ; Laliberte,
Sarah ; Rohrer Bley, Carla
Abstract: Treatment of epithelial sinonasal tumors in cats is not commonly reported. Palliative radiation
protocols have been described more often than definitive-intent protocols. In this multi-institutional
retrospective study, we included 27 cats treated with single-modality radiotherapy. Cats were irradiated
using 10 daily fractions of 4.2Gy. Three cats (11.1%) experienced a complete clinical response and 17
(63%) had a partial clinical response. Stable clinical disease was noted in three cats (11.1%). Four
cats (14.8%) showed progression within 3 months following treatment. The median time to progression
for all cases was 269 days (95% CI: 225;314). The proportion of cats free of progression at 1 and 2
years was 24% (95%CI: 22%;26%) and 5% (95%CI: 5%;6%), respectively. None of the prognostic factors
evaluated were predictive of outcome (anemia, tumor volume at the time of staging, modified Adams
stage, intracranial involvement, facial deformity, epistaxis, inappetence or weight loss). Median overall
survival (OS) for all deaths was 452 days (95%CI: 334;571). The proportion of cats alive at 1 and 2 years
was 57% (95%CI: 37%;77%) and 27% (95%CI: 25%;29%), respectively. Surprisingly, cats with epistaxis
had a longer median OS of 828 days (95%CI: 356;1301) compared to 296 days (95%CI: 85;508) in cats
without epistaxis, (p=0.04, Breslow). Radiation therapy used as a single modality for the treatment of
feline sinonasal carcinoma improved clinical signs and was well tolerated.
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Treatment of epithelial sinonasal tumors in cats is not commonly reported. In the newer 
reports palliative radiation protocols have been described more often than definitive-intent 
protocols. In this multi-institutional retrospective study, we included 27 cats treated with 
single-modality radiotherapy. Cats were irradiated using 10 daily fractions of 4.2Gy. Three 
cats (11.1%) experienced a complete clinical response and 17 (63%) had a partial clinical 
response.  Stable clinical disease was noted in three cats (11.1%). Four cats (14.8%) showed 
progression within 3 months following treatment. The median time to progression for all 
cases was 269 days (95% CI: 225;314). The proportion of cats free of progression at 1 and 2 
years was 24% (95%CI: 22%;26%) and 5% (95%CI: 5%;6%), respectively. None of the 
prognostic factors evaluated were predictive of outcome (anemia, tumor volume at the time 
of staging, modified Adams stage, intracranial involvement, facial deformity, epistaxis, 
inappetence or weight loss). Median overall survival (OS) for all deaths was 452 days 
(95%CI: 334;571). The proportion of cats alive at 1 and 2 years was 57% (95%CI: 37%;77%) 










and 27% (95%CI: 25%;29%), respectively. Surprisingly, cats with epistaxis had a longer 
median OS of 828 days (95%CI: 356;1301) compared to 296 days (95%CI: 85;508) in cats 
without epistaxis, (p=.04, Breslow). Radiation therapy used as a single modality for the 
treatment of feline sinonasal carcinoma improved clinical signs and was well tolerated but 

















Sinonasal neoplasms represent 1-8.4% of all tumors in cats and about 90% are 
malignant.(1, 2) Nearly half of sinonasal tumors in cats are of epithelial origin.(3, 4) 
Treatments such as surgery(1, 5), combination surgery and radiation therapy(1), and radiation 
therapy alone(6, 7) are described. Chemotherapy as a single modality is not commonly 
reported in cats with epithelial neoplasms of sinonasal origin. Carboplatin was used for 
chemoembolization after postoperative tumor recurrence in one patient that survived for over 
800 days.(8) Radiation therapy on gross disease or after surgery is treatment of choice in 
head and neck tumors in human patients.(9) 
Treatment of epithelial sinonasal tumors in cats is not well established and in the 
newer reports palliative radiation protocols are described more often than definitive-intent 
protocols.(3, 7, 10, 11)While radiation therapy seems to be the best option due to the complex 
anatomy of the cat’s nasal passages (wide surgical margins impossible), it is unclear if  
patients would benefit from a more dose- or schedule-intensive protocol.(12) While some 
studies(1, 3, 13) in the past reported outcome data of different nasal tumor histologies 
together, nasal epithelial tumors most likely have an inferior prognosis compared to 
lymphomas.(7, 10, 12, 14) It is unclear if the outcome of epithelial tumors can be improved, 
even if a more intensive protocol is used. In the dog, radiation therapy for sinonasal tumors is 
standard of care and the long-established definitive-intent protocol of 10x4.2Gy is still often 
used.(15-17) 
Two previous retrospective studies(3, 10) described radiation therapy for epithelial 
sinonasal neoplasms using palliative protocols and two investigated non-lymphoproliferative 
neoplasms of the nasal cavity treated with definitive-intent protocols.(7, 11) Median overall 
survival was described as favorable, varying between 11.5-14.4 months, however confidence 










intervals were not reported.(3, 7, 10) Prognosis was negatively impacted in cats that had a 
loss of appetite at the time of therapy and purebred cats seemed to fare better.(3) 
Studies evaluating a standardized radiation treatment protocol in cats with epithelial 
sinonasal tumors are lacking, likely in part as a result of the relative rarity of these tumors.  
The median survival times above were similar between the different studies regardless of 
treatment intent (palliation vs. definitive intent). However, there was a  large disparity in the 
outcome, survival times were varying between 21-2391 days in one study(3), and between 
153-477 days(10) and 30-1080 days(7) in two other studies. This disparity could have several 
causes: the lack of standardization in tumor type (epithelial and non-epithelial tumors are 
described together); different treatment approaches including varying radiation prescriptions 
and protocols (2-6 fractions of 4-8.1Gy per fraction(3, 10), with total dose 16-36Gy(3, 10) or 
12x 4Gy(7, 11)); and different irradiation techniques, or due to natural variation in tumor 
biology. Furthermore, due to the relative rarity of this tumor type, only small numbers of cats 
with epithelial tumors were treated.  
In this multicenter retrospective study, we collected information about cats with epithelial 
sinonasal tumors treated with a 10x4.2Gy single-modality radiation protocol. We describe the 
outcome after definitive-intent radiation therapy and investigate the influence of potential 
prognostic variables. 
 
Material and methods: 
Patient Characteristics and Tumor Staging 
Medical records of cats diagnosed with a sinonasal epithelial neoplasm were retrospectively 
reviewed. All cats treated since starting the definitive-intent protocol of 10x4.2Gy were 
included in the study. Cases from three institutions were included: X, X, X. Inclusion criteria 
were a cytological or histopathological diagnosis of an epithelial neoplasm of the sinonasal 










cavity, nasopharynx, or both (based on the original reports, none of the samples were 
reviewed); tumor staging including computed tomography (CT) of the head; thoracic imaging 
both reported by board certified radiologists; treatment with definitive-intent radiotherapy 
using 10x4.2Gy delivered daily Monday to Friday with no adjuvant chemotherapy or surgery; 
availability of treatment planning details; follow up of at least 3 months after radiation unless 
death occurred earlier. Cytological evaluation of the mandibular and medial retropharyngeal 
lymph nodes was at the discretion of the clinician and not mandatory for inclusion. Cats were 
excluded if they had distant metastasis at diagnosis or received prior treatment with radiation 
therapy, chemotherapy or surgery. 
Participating contributors were provided a data collection form for each case. The following 
information was retrieved from the medical records: signalment (breed, age, sex, weight), 
clinical signs before the start of treatment (yes or no: nasal discharge, epistaxis, sneezing, 
facial deformity, stertor, inappetence and weight loss), tumor location (unilateral or bilateral 
nasal cavity, nasopharynx), presence (yes, no) and location of lymph node metastasis; pre-
treatment complete blood count and serum biochemistry (yes, no); pre-radiotherapy 
hematocrit; co-morbidities. Tumors were classified according to the canine modified Adams 
tumor staging system(18) by the participating contributors as follows: stage 1 (tumor 
confined to one nasal passage, paranasal sinus, or frontal sinus, no bone involvement beyond 
turbinates), stage 2 (any bone involvement, but no evidence of orbital or subcutaneous or 
submucosal mass), stage 3 (orbital, nasopharyngeal, subcutaneous or submucosal 
involvement), stage 4 (tumor causing lysis of the cribriform plate). Stage 4 tumors were sub-
classified into those with and without intracranial extension beyond the cribriform plate. If 
the histopathology report was available tumor type  was recorded. Results of the complete 
blood count including hematocrit and abnormal biochemistry results were recorded. Anemia 
was defined as hematocrit below the institution's own laboratory reference range. 











Information collected about radiation therapy included date of start and end of therapy, 
radiation delivery and treatment planning systems, irradiation of regional lymph nodes (yes, 
no), patient immobilization and position verification procedures. The gross tumor volume 
(GTV), clinical target volume (CTV) and planning target volume (PTV) were recorded. 
Target and organ at risk (19) contouring practices were not standardized.  GTV was 
contoured on CT scan (all institutions). CTV expansion was 1cm within the nasal cavity, 
often including bone and soft tissue if tumor was extending outside of the nasal cavity 
(Institution X and X)  and CTV represented 2cm expansion rostral/caudal to GTV within the 
nasal cavity/nasopharynx considering normal tissue planes (Institution X). PTV represented a 
2mm expansion isotropic (common for all institutions). Dose statistics for targets and OAR 
were not recorded.  
 
Follow-up and Response Assessment 
Follow up information gathered from the medical records came from recheck examination 
notes at the treatment institutions or from phone calls to referring veterinarians or cat owners. 
Complete clinical response to treatment was defined as resolution of previously reported 
clinical signs. Partial clinical response was defined as improvement of the previously 
reported clinical signs. When follow up CT was available, tumor response was recorded by 
the contributing participant as a complete response, partial response, stable disease or 
progressive disease based on diagnostic imaging reports in the medical record. Objective 
tumor response criteria were not standardized. When the clinical response conflicted with the 
imaging response, the least favorable response trumped the more favorable one (clinical 
complete response + partial imaging response = partial response). Cats were assessed to have 
stable disease if no clinical improvement or deterioration was noticed on rechecks or 










imaging. Progressive disease was defined as either recurrence of clinical nasal signs that were 
refractory to antibiotics, tumor progression on imaging or development of local or distant 
metastasis. 
Progressive disease was described in terms of time to progression after radiation, location of 
progression, clinical signs at progression, and diagnostic work-up and additional therapy. 
Progression was defined as “local” if relapse occurred at the original tumor site (sinonasal 
cavity and/or nasopharynx and/or regional lymph nodes), or “systemic” if distant metastasis 
was documented. Progressive disease was considered “confirmed” if cytological or 
histopathological confirmation of carcinoma at progression was available or if recurrence of a 
mass at the original location of the tumor was detected by CT. Progressive disease was 
considered “suspected” when there was recurrence of clinical nasal signs that were not 
responsive to systemic treatment such as antibiotics. 
Cats with resolution of nasal signs to antibiotic therapy after radiation were considered to 
have chronic rhinitis as a possible late effect of radiation therapy. 
Radiation toxicity was defined as early effects if occurring < 3 months after radiotherapy and 
late effects if occurring 3 months. Grading of radiation adverse effects was done 
retrospectively from the medical records using the Veterinary Radiation Therapy Oncology 
Group (VRTOG) toxicity criteria.(20) 
 
Statistical analysis 





Version 25). Data were used as submitted in an excel table by the participating contributors. 
Description of quantitative data characteristics, other than time to progression (TTP) and 
overall survival is given by mean (± SD), unless otherwise specified. Description of 










qualitative characteristics is provided in absolute and relative frequencies. A graphical 
assessment and Shapiro-Wilk normality test were performed on all data. TTP was defined as 
the interval between the first day of radiation therapy to confirmed (diagnostic imaging 
and/or cytology) or clinically suspected progression of disease (local, systemic). Cats free of 
progression at the time of data analysis or death or that were lost to follow-up were censored 
for TTP analysis at the date of death, the last hospital visit or last contact by phone with the 
owner or veterinarian. OS was defined as the interval between the first fraction of radiation 
and death. For OS, all deaths were considered events and cats still alive at the time of data 
analysis or lost to follow-up were censored at the last date known to be alive. For the follow-
up time estimate, cats were censored at the time of death. OS and TTP were coded and 
analyzed with Kaplan-Meier survival analysis accompanied by the log-rank or Breslow-
Gehan-Wilcoxon tests. In the absence of crossing of survival curves, the log-rank test was 
applied. Otherwise the Breslow-Gehan-Wilcoxon test was used. The univariate and multiple 
Cox-regression analysis was used to determine whether the following factors were 
significantly associated with TTP or OS: sex, age, weight, anemia, facial deformity, epistaxis, 
inappetence, weight loss, GTV, PTV, CTV, modified Adams tumor stage, intracranial 
involvement, tumor location, locoregional lymph nodes metastases, treatment institution. 
Median TTP and median OS are reported with the corresponding 95% confidence intervals 




Twenty-seven cats diagnosed with an epithelial sinonasal tumor were treated with 10x4.2Gy 
between 2014 and 2018.  None of the cats were excluded. Eleven cats were from the X, 10 
cats from the X and six from X. Eleven were spayed females and 16 were neutered males. 










The most common breed was domestic shorthair (n=25), and two cats were Siamese. Age 
ranged from 6.1-18 years with a mean of 12.7 (± 3.2) years and weight ranged from 2.5-11.8 
kg with a mean of 4.8 (± 1.9) kg. Four of the 27 cats (14.8%) were anemic at the time of 
diagnosis [median hematocrit 39% (IQR: 11.0)]. The most commonly presenting sign was 
nasal discharge in 19 cats (70.4%), 12 (44.4%) of which also had epistaxis. Sneezing was 
present in 16 cats (59.3%), stertor in 12 (44.4%), and 11 cats (40.7%) had a facial deformity. 
Inappetence and weight loss were recorded in six (22.2%) and three (11.1%) cats, 
respectively. Five cats (18.5%) had unilateral nasal disease without nasopharyngeal 
involvement and four (14.8%) had unilateral disease with nasopharyngeal involvement. 
Bilateral presence of the tumor with or without nasopharyngeal disease was seen in eight 
(29.8%) and seven (25.9%) cats, respectively. Tumor was confined to the  nasopharynx in 
three (11.1%) cats. When we grouped the extent of disease according to the modified Adam’s 
staging method for nasal tumors in dogs, four tumors (14.8%) were stage 1, one tumor (3.7%) 
was stage 2, eight tumors (29.6%) were stage 3, and 14 tumors (51.9%) were stage 4. Seven 
of the cats with stage 4 tumors (25.9% of all cats) had intracranial extension beyond the 
cribriform plate. The diagnosis was confirmed by histology in all but one cat. The latter was 
diagnosed cytologically as a carcinoma. The histological reports revealed 19 (73.1%) 
adenocarcinomas, four (15.3%) tubular carcinomas, two (7.7%) undifferentiated carcinomas 
and one (3.8%) squamous cell carcinoma. Immunohistochemistry was not performed. 
Bilateral mandibular lymph nodes were evaluated cytologically in all 27 cats, and 
retropharyngeal lymph node cytology was available for six cats.  Two cats had confirmed 
lymph node metastasis: one in the ipsilateral mandibular lymph node and one in the 
ipsilateral mandibular and prescapular lymph node. In the latter, the diagnosis of metastasis 
was suspected, but not confirmed. The diagnostic and tumor staging work-up included 
hematology, serum biochemistry, and thoracic imaging (radiographs or CT) in all cats. 











Radiation Planning and Treatment 
Computed tomography for treatment planning was performed with either a Brilliance 16-slice 
[Philips Health Care Ltd, Best, Netherlands (cases from X], a LightSpeed 3.X 8-slice [GE 
Medical Systems, Milwaukee, WI, USA (cases from X)] or a BrightSpeed 16-slice [GE 
Healthcare, Milwaukee, WI, USA (cases from X)] CT. The thickness of the slices varied 
between 1.5-2mm. Computed tomography scans of the area of interest were obtained before 
and after intravenous administration of a bolus of contrast medium. The post-contrast images 
were co-registered with the native planning CT images for better delineation. Mean GTV was 
10.5 cm
3
 (± 9.2). Mean CTV was 21.6 cm
3
 (± 13.2). Mean PTV was 34.6 cm
3
 (± 18.7). 
All cats were treated with 10 daily fractions of 4.2Gy using 6 MV x-rays. Twenty-four cats 
(88.9%) were treated with intensity-modulated radiotherapy (IMRT) and 3 (11.1%) with 3D 
conformal radiotherapy (3DCRT) using beam modifying wedges and an 80 or 120 multi-leaf 
collimator (Clinac iX, Varian, Palo Alto, USA; cases from X, and X respectively). IMRT was 
delivered using dynamic IMRT (Clinac iX, Varian, Palo Alto, USA; cases from X, X in 14 
cats and helical tomotherapy (TomoTherapy HiArt Treatment System
®
, Accuray Inc., 
Sunnyvale, CA, USA; cases from X in 10 cats. In thirteen patients a bolus was placed on the 
cats' heads in order to create sufficient dose build-up and reduce the depth of the maximal 
dose (Dmax). This consisted either of a Superflab
 
made of synthetic oil gel (7 cases from X) 
or a custom-made water equivalent bolus made of gauze and vaseline (6 cases from X). 
Image-guidance was performed using daily kilovolt (kV)-kV orthogonal radiographs (n=4, 
cats from X), kV-cone-beam CT (CBCT) once to three times during the treatment course 
(n=5, cats from X), kV-cone-beam CT (CBCT) twice a week for a total of 4 CBCT (n=2, cats 
from X), daily helical MV-CT (n=10 cats from X), and daily kV-CBCT (n=6, cats from X). 
At all institutions, cats were under general anesthesia and immobilized for both the planning 










CT and daily treatment using a customized bite block and vacuum mattress. For dynamic 
IMRT and 3DCRT treatment planning, the Eclipse™ Treatment Planning system (version 
10.0, 11.5.0 or 15.1, Varian Oncology Systems, Palo Alto, California) was used with the 
AAA photon dose calculation model with heterogeneity correction. Tomotherapy plans were 
created using the convolution superposition algorithm, including heterogeneity correction 
(Tomotherapy Planning Station Hi-Art versions 3 to 5). The planning aim for all cats was to 
deliver dose to the PTV such that 95% of the PTV received between 95-107% of the 
prescribed dose. However, due to the retrospective nature of the study there was no 
information on how many of the plans adhered to those aims. Maximum, mean and minimum 
dose is reported in Table 1. 
Dosimetric quality assurance was performed by a medical physicist for all IMRT treatment 
plans delivered at all institutions and considered within tolerance. Median overall treatment 
time was 12 days (range 12-18 days; IQR: 2.0). The treatment delay was due to breaks over 
the weekend(s) and bank holidays. The locoregional lymph nodes, including bilateral 
mandibular and bilateral medial retropharyngeal nodes, were prophylactically irradiated 
using the same treatment plan in four of the 27 cats (14.8%). Two cats (7.4%) with 
(suspected) locoregional metastasis received radiation of the affected lymph nodes using the 
same treatment plan. The others 21 cats (77.8%) received no irradiation of the locoregional 
lymph nodes.  Cats were prescribed supportive medications including steroids, non-steroidal 
anti-inflammatory drugs (NSAID) and/or antibiotics as needed to manage early radiation 
toxicity. 
 
Radiation Toxicity, Follow-up and Outcome 
Follow-up was not standardized. Toxicities were graded during the regular follow-up visits. 
Data regarding toxicities were extracted from the clinical records (grade and/or photograph). 










Early radiation toxicity was assessed in all cats between 1-3 weeks after the end of radiation 
therapy. Twelve (44.4%) cats exhibited no side effects and 15 cats (55.6%) developed mild to 
moderate radiation toxicity: mild grade 1 skin reactions were observed in 12 cats (44.4%), 
grade 1 mucosal reactions in three cats (11.1%), grade 1 ocular reactions in two cats (7.4%), 
moderate grade 2 ocular and mucosal reactions in one cat (3.7%), and moderate grade 3 
mucosal reaction in one cat (3.7%). All but four cats were assessed for late radiation toxicity. 
The recommended re-check schedule for assessment of late toxicity was every 3 months until 
12 months post RT and then every 6 months or every 3 months until 24 months post RT but 
this varied between the different institutions and cats. Nine cats (33.3%) developed late side 
effects: mild, grade 1 skin reactions (leukotrichia, alopecia) were seen in eight cats (29.6%), 
grade 1 ocular reactions in five cats (18.5%) and moderate grade 2 ocular reactions in one cat 
(3.7%). Eleven of 27 (40.7%) cats showed signs of intermittent or chronic rhinitis. Central 
nervous system or bone toxicity were not reported. Three cats treated with 3DCRT displayed 
similar side effects as cats treated with IMRT. One developed early (skin) and one late (eye) 
side effects, both VRTOG grade 1. 
Clinical response to radiation was evaluated in all 27 cats. Three cats (11.1%) 
experienced a complete clinical response and 17 (63%) had a partial clinical response. Stable 
clinical signs were noted in three cats (11.1%). Four cats (14.8%) had a rapid worsening of 
clinical signs within the first three months after radiation therapy and were considered 
progressive without notable improvement. Objective tumor response based on imaging was 
difficult to assess, as there were no standardized time points. The motivation to perform a 
post-treatment CT scan was mainly if progression was suspected based on the clinical 
examination. Follow-up CT was performed between 3 and 18 months after radiotherapy in 
17/27 cats. Four of these 17 cats had a partial response, six had stable disease  and seven had 
progressive disease. 










The mean follow-up time for all cats was 987 days, (95% CI: 756;1215, range 119-1262). 
During this time, a total of 23 cats (85.2%) developed suspected local progressive disease. In 
two cats (7.4%), previously free of metastases, disease progression to the regional lymph was 
cytologically confirmed. The latter disease progression was cytologically confirmed. None of 
the cats had documented systemic progression. 
The median TTP for all cases was 269 days (95% CI: 225;314). The proportion of cats free of 
progression at 1 and 2 years was 24% (95%CI: 22%;26%) and 5% (95%CI: 5%;6%), 
respectively (Figure 1). We found no significant difference in TTP between the 3 institutions: 
median TTP for 11 cats treated at the X was 225 days (95%CI: 111;340, range 75-1262), 
median TTP for 10 cats treated at the X was 168 days (95%CI: 26;311, range 52-521), and 
median TTP for 6 cats treated at the X was 296 days (95%CI: 204;314, range 247-389), 
(p=.06, log-rank).  None of the factors including anemia (p=.20, log-rank), tumor size (GTV) 
at time of staging (p=.95, log-rank), modified Adams stage (p=.10, log-rank), intracranial 
involvement (p=.10, log-rank), facial deformity (p=.95, log-rank), epistaxis (p=.15, log-rank), 
inappetence (p=.06, log-rank) or weight loss (p=.74, log-rank) were predictive of TTP. 
Three cats were re-irradiated after developing progressive disease: all of them received an 
additional five daily fractions of 4Gy 281, 389, and 521 days after the first treatment. An 
additional six cats received adjuvant chemotherapy at progression: toceranib was prescribed 
to four cats, and carboplatin and doxorubicin were used in one cat each. Twelve cats received 
NSAIDs and/or antibiotics for supportive treatment of progressive clinical signs. 
Information regarding outcomes relied on consultation in the radiation facility or with the 
private veterinarian in 17 cases and on telephone follow-up with the owners in the remaining 
10 cases. Median OS for all deaths was 452 days (95%CI: 334;571) (Figure 2). We found no 
significant difference in OS between the 3 institutions: median OS for 11 cats treated at the X 
was 452 days (95%CI: 350;555, range 153-1262), median OS for 10 cats treated at the X was 










575 days (95%CI: 0;1365, range 67-829), and median OS for 6 cats treated at the X was 396 
days (95%CI: 241;552, range 256-515), (p=.780, log-rank). 
The proportion of cats alive at 1 and 2 years was 57% (95%CI: 37%;77%) and 27% (95%CI: 
25%;29%), respectively. Cats with epistaxis lived significantly longer, with a median OS of 
828 days (95%CI: 356;1301) vs. 296 days (95%CI: 85;508) in cats without epistaxis, (p=.04, 
Breslow) (Figure 3). None of the other factors were predictive of OS. The TTP and survival 
of the two cats with initial locoregional metastases were 225, respectively 355 days, and 452, 
respectively 362 days. 
Twenty-one animals (77.8%) died. Fifteen (55.6%) deaths were tumor-related and 5 (18.5%) 
were tumor-unrelated (car accident, high grade intestinal lymphoma, chronic kidney disease). 
Cause of death was not known in 1 cat (3.7%). In all cats with tumor-related death, the cause 
was local progression and progressive clinical signs. All cast died without known systemic 
metastasis or without clinical signs related to systemic metastasis. 
 
Discussion 
As all cats in our study were staged with CT, we assessed the extent of disease using 
the modified canine Adams staging system.(18) Local tumor extent has not been shown to be 
predictive of outcome in cats with nasal tumors in previous studies(7), and was not associated 
with TTP or OS in this study either. Similarly, tumor extension into the calvarium, which 
affected 25% of cats in this study, was not a prognostic indicator. Consistent with previous 
studies(18, 21), most cats in this cohort presented with advanced stage disease classified as 
stage 3 or 4 according to the modified Adams system. It is unclear why cats are presented in 
rather advanced disease stages. It is possible that cats with nasal tumors are misdiagnosed as 
having chronic rhinitis, the second most common cause of nasal disease in cats(22), and that 
work up including advanced imaging and other diagnostics is delayed while cats are treated 










symptomatically with steroids, NSAIDs and/or antibiotics.(21-23)  Cats in previous studies 
seemed to show only mild signs with stage 4 disease, despite having measurable intracranial 
tumor extension.(3, 7, 10) Stage 4 disease is a negative prognostic factor in dogs with nasal 
tumors, reducing overall survival time.(18, 24, 25) In cats, however, we found no influence 
of stage on outcome based on the modified Adams system. Similarly, most of the other 
variables we evaluated, including anemia at time of staging, tumor size, facial deformity, 
inappetence or weight loss were not predictive of TTP or OS.  The only prognostic variable 
was epistaxis, which correlated with longer OS.  This is contrary to dogs with nasal 
carcinoma, where epistaxis is associated with a 2.3 fold increased risk of dying.(26) 
The side effect profile observed in this cohort of cats treated with conformal radiation 
delivery techniques (IMRT in 24/27) was favorable. The majority of side effects were mild 
(grade 1) or moderate (grade 2). Toxicity profiles would be expected to be different with less-
conformal radiation delivery systems. Overall, this study suggests that the protocol described 
herein is safe and well-tolerated when IMRT is used and can be recommended for the 
treatment of sinonasal carcinoma in cats. However, since dose statistics for organs at risk 
were not recorded it is not possible to correlate toxicity and radiation dose. 
After definitive-intent radiation therapy using 10x4.2Gy, we found local tumor 
progression or progression of nasal signs in the majority of cats (85.2%). Median TTP was 
short at 9 months, with 76% of cats showing progression at 1 year. This high rate of local 
treatment failure was also found by other colleagues, where 79.8% of the cats (epithelial or 
mesenchymal tumors)(7) and 61.3% of the cats (epithelial tumors or localized lymphoma)(3) 
progressed locally at one year. However, most studies, including ours, are limited by a lack of 
standardized follow-up imaging to assess tumor status. It is unclear to what extent our 
assessment of progressive disease based on nasal signs being unresponsive to antibiotics 
represents true tumor progression. Similarly, tumor response to radiation was difficult to 










objectively evaluate and was assessed based on resolution of nasal signs. A prospective study 
with regular, standardized follow up imaging is necessary to accurately estimate TTP. 
Clinical signs improved after radiation therapy in most cats in this study (74%). Three 
cats experienced complete resolution of clinical signs and 17 had partial resolution or 
improvement of signs.  It is notable, however, that four cats experienced rapid worsening of 
clinical signs within 3 months after radiation, without improvement. 
In the present study, the OS was approximately half a year longer than the TTP, which could 
be associated with the response of some cats to the rescue protocols instituted at disease 
progression (chemotherapy, palliative radiotherapy), and/or to slow progression of disease 
and the level of tolerance of cats to the clinical signs. The median OS was 15 months 
(95%CI: 11.1-19.0). Interestingly, previous radiation studies describing more palliative 
approaches have reported median OS times of 15 months (95%CI: 6.8-23.8)(3) and 12.6 
months(10), confidence interval was not available for the latter study. Notwithstanding, the 
disparity in reported outcomes in the literature is wide. This could be due to differences in the 
tumors themselves (biological factors),  treatment-related factors (effectiveness of RT 
delivery, treatment planning and delivery) or to limitations of study design (small case 
numbers, different tumor types described together, disparity of the treatment protocol within 
the study).  It is not clear if there is truly disparity in outcome among cats with epithelial 
sinonasal tumors or if the variation in reported outcomes is the result of study bias. Future 
studies should aim to determine the role, if any, for more intensive protocols such as the one 
described here versus that of more palliative radiation approaches. 
We acknowledge the limitations inherent with retrospective and multicenter studies. Tumor 
staging, treatment planning and delivery, as well as follow-up procedures were not 
standardized.  Importantly, the difficulty in objectively assessing tumor progression without 
standardized follow-up imaging can under- or overestimate tumor response and progression.  










Furthermore, although the three institutions used the same radiation therapy protocol, the 
quality of treatment plans with respect to tumor dose coverage and OAR exposure was not 
evaluated. Dose distribution is critical to radiation effectiveness, as well as to toxicity, and 
underdosage of the tumor can contribute to treatment failure. In the head and neck area of 
cats, the absorbed dose to PTV can be lower than intended or recommended, most likely due 
to shortcomings of adequate bolus placement or due to air soft tissue interfaces such as in the 
frontal sinus or oral cavity.(12, 17, 27) Such underdosage can contribute to treatment failure 
even in the face of a protocol with sufficiently high anti-tumor dose. Underdosages due to 
lack of bolus can be prevented by placement of bolus material on the cats’ head. Adherence 
to recommended dose distribution guidelines and accurate reporting of dose delivered to 




Radiation therapy used as a single modality for the treatment of sinonasal carcinoma in cats 
improved clinical signs and resulted in a median survival time of 15 months in a cohort of 27 
cats treated with 10x4.2Gy.  Using conformal delivery systems, the treatment was well 
tolerated, but progression of nasal signs occurred within 9 months in the majority of cats. 
 
Data accessibility 
The data that support the findings of this study are available from the corresponding author 
upon reasonable request 
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Kaplan-Meier plot showing the proportion of the 27 cats with sinonasal carcinoma alive: 
median overall survival 452 days (95%CI: 334;571). The vertical dashed lines represent the 
time points of 1 and 2 years, with 57% (95%CI: 37%;77%) and 27% (95%CI: 25%;29%) of 
cats alive, respectively. The small vertical lines represent censored cases. 
 
Figure 2. 
Kaplan-Meier plot showing time to progression for all 27 cats with sinonasal carcinoma after 
radiotherapy: median 269 days (95% CI: 225;314). The vertical dashed lines represent the 
time points of 1 and 2 years, with 24% (95%CI: 22%;26%) and 5% (95%CI: 5%;6%) of cats 
free of progression, respectively. The small vertical lines represent censored cases. 
 
Figure 3 
Kaplan-Meier plot showing the differences in survival for those cats with (red line) and 
without epistaxis (blue line). The median OS for cats with epistaxis was 828 days (95%CI: 
356;1301) vs. 296 days (95%CI: 85;508) in cats without epistaxis, (p=.04, Breslow). 
 
Table 1 
Target volumes: mean volumes and absorbed doses (n=27) 
 


























(mean ± SD) 
[Gy] 
Dmean 
(mean ± SD) 
[Gy] 
Dmin 
(mean ± SD) 
[Gy] 
GTV 10.5 ± 9.2 45.0 ± 1.7 42.7 ± 0.5 39.3 ± 2.8 
CTV 21.6 ± 13.2 45.6 ± 1.9 42.7 ± 0.5 37.6 ± 3.5 
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